Company Information

ZIM LABORATORIES LTD.

NSE : ZIMLABBSE : 541400ISIN CODE : INE518E01015Industry : Pharmaceuticals & DrugsHouse : MNC
BSE106.010.81 (+0.77 %)
PREV CLOSE ( ) 105.20
OPEN PRICE ( ) 105.77
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 524
TODAY'S LOW / HIGH ( )105.36 106.75
52 WK LOW / HIGH ( )79.5 128.45
NSE106.210.79 (+0.75 %)
PREV CLOSE( ) 105.42
OPEN PRICE ( ) 105.42
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21386
TODAY'S LOW / HIGH( ) 103.87 107.00
52 WK LOW / HIGH ( )79.49 128.9
ChairmanAnwar Siraj Daud
Managing DirectorAnwar Siraj Daud
Company SecretaryPiyush Siddeshwar Nikhade
Whole Time Director - FinanceZulfiquar Murtaza Kamal
Non Executive Independent DirectorKavita Loya
Padmakar Shrinivas Joshi
Kamlesh Shende
Ashok Bhatia
Whole Time DirectorNiraj Pukhraj Dhadiwal
Prakash Pralhadrao Sapkal
Incorporation Year : 1984

Registered Office :

Address : Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, Nagpur,
Maharashtra-440013 .

Phone : 0712-2981960

Email :  info@zimlab.in 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.